Porcine reproductive and respiratory syndrome (PRRS) is a devastating disease which impacts the pig industry worldwide. The disease is caused by PRRS viruses (PRRSV-1 and -2) which leads to abortions and other forms of reproductive failure in sows and severe respiratory disease in growing pigs. Current PRRSV vaccines provide limited protection; only providing complete protection against closely related strains. The development of improved PRRSV vaccines would benefit from an increased understanding of epitopes relevant to protection, including those recognized by antibodies which possess the ability to neutralize distantly related strains. In this work, a reverse vaccinology approach was taken; starting first with pigs known to have a broadly neutralizing antibody response and then investigating the responsible B cells/antibodies through the isolation of PRRSV neutralizing monoclonal antibodies (mAbs). PBMCs were harvested from pigs sequentially exposed to a modified-live PRRSV-2 vaccine as well as divergent PRRSV-2 field isolates. Memory B cells were immortalized and a total of 5 PRRSV-specific B-cell populations were isolated. All identified PRRSV-specific antibodies were found to be broadly binding to all PRRSV-2 isolates tested, but not PRRSV-1 isolates. Antibodies against GP5 protein, commonly thought to possess a dominant PRRSV neutralizing epitope, were found to be highly abundant, as four out of five B cells populations were GP5 specific. One of the GP5-specific mAbs was shown to be neutralizing but this was only observed against homologous and not heterologous PRRSV strains. Further investigation of these antibodies, and others, may lead to the elucidation of conserved neutralizing epitopes that can be exploited for improved vaccine design and lays the groundwork for the study of broadly neutralizing antibodies against other porcine pathogens.

Keywords: porcine reproductive and respiratory syndrome virus, humoral immunity, broad neutralization, B cell, monoclonal antibody, glycoprotein-5
INTRODUCTION

Porcine reproductive and respiratory syndrome virus (PRRSV) can spread rapidly among pigs through multiple routes of transmission, including aerosolization, causing severe respiratory disease that often leads to secondary infections and death in nursery age pigs (1). In sows, it is common to observe sudden loss of litters late in gestation, along with stillbirth and weak piglets in farrowed litters (1). PRRSV infection can also remain persistent in pigs for several months before it is completely cleared (2, 3). Because of these clinical manifestations and viral persistence, PRRSV remains an economically devastating disease in swine herds worldwide (4, 5).

Several antibody epitopes are suspected to be involved in neutralization of PRRSV, but there is a large gap in knowledge of how individual antibodies are capable of neutralizing PRRSV (6, 7). The majority of historical neutralization studies have concentrated on the PRRSV structural protein GP5, with interest in epitope B (amino acids 36-52), which has been proposed as an epitope for broad neutralization (8–12). It is important to note that while GP5 is required for the formation of viral particles, it is not required for virus to be infectious, suggesting inhibition of the GP5 viral protein alone may not lead to full neutralization of the virus (13). Along similar lines, several studies have also determined that GP5 specific antibody responses are non-neutralizing, however these studies appear to conflict with previously published studies (14–20). Recent work has determined that the PRRSV GP2-GP3-GP4 minor glycoprotein complex is key to viral entry into the host macrophage, through its interactions with CD163 (21–23). Based on these findings, other studies have also suggested sites of neutralization on GP4 and GP3 inducing renewed interest in the GP2-GP3-GP4 complex as a target for neutralization (24–28).

Passive immunization of sows with PRRSV-neutralizing antibodies have been shown to prevent viremia and viral transfer to the fetus, but an individual pig’s clearance of virus does not always correlate to a neutralizing antibody response (29, 30). The humoral immune response against PRRSV generates a large array of PRRSV-specific antibodies, but these antibodies vary in neutralizing capacity from non-neutralizing, to homologously neutralizing, and, rarely, to broadly neutralizing (31, 32). Current vaccines against PRRSV provide limited homologous and, rarely, to broadly neutralizing protection, often restricted to closely related viruses (33). Cross-protection has been shown to be achievable in pigs, but it does not always occur and seems to require multiple heterologous PRRSV exposures, such as vaccination as well as heterologous viral challenge (31, 34–36).

We theorize that exposure to diverse PRRSV strains enhances and improves the likelihood of the generation of broadly neutralizing antibodies. Therefore, to better evaluate PRRSV neutralizing antibodies, CD21+, IgG+ memory B cells from pigs whose sera broadly neutralized PRRSV were isolated and immortalized (37). Clonal populations of immortalized B cells that secreted PRRSV-specific antibodies were obtained. Antibodies isolated from these populations were mainly found to be GP5-specific and broadly binding to PRRSV-2 strains. One antibody was determined to neutralize homologous but not heterologous PRRSV strains.

MATERIALS AND METHODS

Cells, Viruses, and In Vitro Infection

Archived samples from two parity 1 sows that had received two PRRSV ATP vaccinations and one or two PRRSV-2 field strain inoculations over a period of several months were collected 90 days after the final live virus exposure. Samples used for this study were peripheral blood mononuclear cells (PBMCs), splenocytes and serum.

Evaluation of antibody specificity and neutralization capacity was determined using the following MARC-145 cell adapted PRRSV strains: ATP (PRRSV-2, GenBank accession: EF532801.1), VR2332 (PRRSV-2, GenBank accession: MT269876), MN184 (PRRSV-2, GenBank accession: MT269877), 1-7-4 (PRRSV-2, GenBank accession: MN175677), 1-4-4 (PRRSV-2, GenBank accession: MT269878), 1-3-4 (PRRSV-2, GenBank accession: MT269879), 1-26-2 (PRRSV-2, GenBank accession: KF724400), SDEU (PRRSV-1, GenBank accession: MN175678) and Leystad virus (PRRSV-1, GenBank accession: M96262.2). For antigen-baiting of PRRSV-specific B cells, PRRSV-2 VR2332 was labeled with Alexa Fluor-647 (AF647) as previously described for dengue virus (38). A phylogenetic tree showing the relationship between these PRRSV strains was created using both whole genome and ORF5 sequences, aligned with ClustalW using Mega version X gene analysis software (39). MARC-145 cells were grown and passaged 90 days after the final live virus exposure. Samples used for this study were peripheral blood mononuclear cells (PBMCs), splenocytes and serum.

B Cell Immortalization, Culture, and Flow Cytometry

B cell immortalization was performed starting with PBMCs from pigs showing evidence of heterologous neutralization which were previously isolated and cryopreserved (40). PBMCs were thawed from liquid nitrogen storage and cultured, at 2 × 10⁶ PBMCs per well, for 24 h in 24 well tissue culture plates in IMDM media containing 10% FBS with the addition of 5 × 10⁴ irradiated CD40L expressing L cells (CD40L-L cells; AIMM Therapeutics, The Netherlands), and 50 ng/ml recombinant murine IL-21 fusion protein (IL-21; AIMM Therapeutics). PBMCs were then stained with fixable viability dye eFluor780 (1:200 dilution, eBioscience, San Diego, CA) to determine viability, PE mouse anti-porcine CD21 mAb (1:1,000 dilution, Abcam, Cambridge, MA), AF647 mouse anti-porcine IgG mAb (1:1,000 dilution, Cohesion Biosciences, London, UK) and biotinylated goat anti-porcine IgM polyclonal antibody (1:4,000 dilution, Bethyl Laboratories, Montgomery, TX) with Brilliant Violet 421 streptavidin to detect IgM labeling (1:3,000 dilution, BioLegend, San Diego, CA, USA). Cells (2.5 × 10⁵) were then sorted on a BD FACSAria II flow cytometer (BD Biosciences, San Jose, CA, USA) at the University of Minnesota Flow Cytometry Resource facilities and returned to a 24-well, tissue culture treated plate as described above, for 36 h. Sorted B cells were then mixed with the immortalization vector (GALV pseudotyped LZRS-Bcl6-2A-BclxL-IRES-GFP; AIMM Therapeutics), in equal volumes, and treated as previously described (37). Immortalized B cells were cultured for 7 to 9 days in IMDM media containing 10% FBS and evaluated for GFP expression, a marker of
successful immortalization, via flow cytometry. Cells were then resorted via flow cytometry into populations of 20 B cells based on either binding to AF647 labeled PRRSV-2+/GFP+ (BNW7) or IgG+/GFP+ (BNW4) to 96-well, 300 µl volume, tissue culture treated plates, and returned to culture for 3 weeks. Cultured multi-cell populations were supplemented every 3 to 4 days with 25 µl of 10% FBS IMDM containing 2 µl of 5 µg/ml IL-21 and 20,000 irradiated CD40-L cells. Multi-cell populations were examined for PRRSV specific antibodies by immunofluorescence and positive populations were resorted into single cell populations using flow cytometry and grown in culture for 3 to 4 weeks. Again, cultures were supplemented every 3 to 4 days with 25 µl of 10% FBS IMDM containing 2 µl of 5µg/ml IL-21 and 20,000 CD40-L cells. Flow cytometry data was analyzed using FlowJo software v10 (Becton Dickinson, Franklin Lakes, NJ). CD40L expressing mouse L-cells, recombinant human IL-21, and the immortalization vector, GALV pseudotyped LZRS-Bcl6-2A-Bcl-xL-IRES-GFP were graciously provided by AIMM Therapeutics (41). The retroviral vector containing Bcl-6 and Bcl-xL was generated by a for-profit company, AIMM Therapeutics, which makes the deep-frozen virus supernatant available. Obtaining the deep-frozen virus supernatant requires an MTA (http://www.aimmtherapeutics.com/partnering/academic-collaboration/) that includes financial obligations.

**Immunofluorescence Assay**

An immunofluorescence assay (IFA) was performed to identify PRRSV-specific antibodies secreted from immortalized B cell populations. B cell supernatants from multi-cell populations were screened after 3 weeks of culture for the presence of virus binding antibodies by IFA. Supernatants from clonal populations were obtained after 5–7 days of culture and the presence of PRRSV-specific antibodies were evaluated by IFA. For the IFA assay, MARC-145 cells were plated at 1 × 10⁴ cells/well in 96-well plates in complete MEM media (cMEM; MEM with non-essential amino acids, 0.075% sodium bicarbonate, 25 mg/ml gentamycin sulfate, 10mM HEPES and 10% FBS). After two days in culture, 50 µl of 2 × 10⁵ TCID₅₀/ml PRRSV strain VR2332 or ATP (MOI=0.1) was added to each well and incubated at 37°C, 5% CO₂ for 1 h. Without removing the viral inocula, 150 µl of cMEM media was added to each well and cells were incubated for an additional 23 h. Media was then removed and cells were fixed using methanol. B cell supernatants (100 µl) or serum (100 µl of a 1:2000 dilution) were then added to fixed wells containing infected cells and incubated at 37°C, 5% CO₂ for 1 h. Wells were washed and 50 µl of a 1:100 dilution of secondary antibody, FITC conjugated goat anti-pig IgG antibody (Bethyl Laboratories, Montgomery, TX), was added and incubated for 1 h. Wells were washed and cell nuclei were stained using bisbenzimide for 20–30 min. Stained monolayers were visualized using a Nikon TE2000 fluorescent microscope (Nikon, Tokyo, Japan) at the University of Minnesota CBS Imaging Center using SPOT basic imaging software (SPOT Imaging Solutions, Sterling Heights, MI, USA). A commercial PRRSV antibody, SR30-A at a 1:1000 dilution (RTI, Brookings, SD, USA) was used as a positive control. Serum from a PRRSV naive pig was used as a negative control. At least two replicates were run for each antibody containing sample.

**Antigen-Antibody Binding Assay**

Supernatants from B cell cultures and pig serum were examined for their ability to bind recombinant structural and non-structural PRRSV proteins using ELISA. PRRSV structural proteins, GP2, GP3, GP4, GP5, GP5-M, M 5’ (N-terminal 32 aa), M 3’ (C-terminal 88 aa), and nucleocapsid (N), and PRRSV non-structural proteins, NSP2P, NSP4, NSP7, NSP8, NSP11, that were previously expressed and purified, were examined (42–44). All PRRSV proteins were previously expressed in *E. coli*, contain a his-tag, and were purified using metal affinity chromatography (44). Correct folding of protein constructs was not verified. Proteins were constructed from PRRSV-2 VR2332 sequence, with the exception of GP2, GP3 and GP4, which were constructed from PRRSV-2 SD95-21 (GenBank accession: KC469618.1), which has a 99.98% nucleotide identity and 100% amino acid homology within GP2, GP3 and GP4 to VR2332, and were kindly provided by Dr. Ying Fang (University of Illinois, Champaign, IL, USA). ELISAs were performed as previously described (42, 45). Briefly, 96 well, ELISA plates were coated with 100 to 500 ng of recombinant PRRSV protein at 4°C overnight, followed by the addition of primary antibody from 100 µl of immortalized B cell culture supernatants or 100 µl of 1:50 dilution of pig serum, a secondary antibody of horseradish peroxidase (HRP)-conjugated goat anti-pig IgG antibody at a 1:100,000 dilution of (Bethyl Laboratories), and color was developed using a TMB substrate solution (Seracare Life Sciences, Milford, MA, USA). Absorbance at 450nm (A₄₅₀) was determined using a BioTek Epoch ELISA plate reader (BioTek, Winooski, VT, USA). Positive and negative controls were run on each plate, as described above. At least two replicates were run for each antibody containing sample.

**PRRSV Neutralization Assay**

Neutralizing antibody assays were performed on MARC-145 cell monolayers as previously described (34). IgG-specific antibodies from B cell supernatants were isolated using the Thermo Scientific Pierce Protein A IgG Purification Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. Antibodies were produced and purified at least 3 separate times. The concentration of IgG in each purified sample was determined using a pig IgG ELISA according to manufacturer’s protocols (Pig IgG ELISA Quantitation Set, Bethyl Laboratories). Isolated antibodies were adjusted to a concentration of 55ng/ul for use in the neutralization assay. Isolated antibodies (or control serum) were serial diluted 2-fold and mixed with the desired PRRSV strain. For both ATP and VR2332, infection was performed at an MOI of 0.06 and for SDEU the MOI was 0.02. The primary antibody SR-30A (mouse anti-PRRSV nucleocapsid antibody, SR30-A, RTI) was used at a 1:10,000 dilution and secondary antibody HRP-conjugated goat anti-mouse IgG (Bethyl Laboratories) was used at a 1:10,000 dilution. Color was
developed using TMB solution (Seracare Life Sciences, Milford, MA, USA) and the optical density (OD) at 450 nm was obtained using a BioTek Epoch plate reader (BioTek). Background (uninfected MARC-145 cells) subtracted OD values were used to determine the percent inhibition of infection at each dilution as compared to virus only wells. At least 3 replicate neutralization assays were performed for each of the viruses using at least 2 batches of purified antibodies.

RESULTS

Isolation, Immortalization, and Identification of PRRSV-Specific B Cells

Memory B cells from two pigs, BNW4 and BNW7, that had been exposed several times to both PRRSV ATP vaccine and field virus and whose sera neutralized a broad range of PRRSV strains (Supplementary Figure 1), were sorted and immortalized. A total of 480 multi-cell B cell populations were obtained from pig BNW7 through cell sorting based on binding of AF647 labeled PRRSV-2 VR2332, GFP presence (marker for immortalization), and surface expression of IgG. For pig BNW4, a total of 96 multi-cell B cell populations were sorted based on GFP and IgG expression. From 576 total screened populations, 5 PRRSV-specific immortalized B cell multi-cell populations were identified, four from pig BNW7 (p1, p5, p9 and p10) and one from pig BNW4 (p14). Based on the low rate of positive populations from both the BNW4 and BNW7 sorts, the virus-specific B cell enrichment was likely ineffective, and more than likely PRRSV specific B cells were identified by chance. Clonal populations were then isolated and propagated for two of the populations (BNW7p5c4 and BNW7p10c5). Supernatants from the 2 clonal populations and 3 multi-cell populations were examined for the ability of the secreted antibodies to bind V2332 infected MARC-145 cells (Figure 1). A difference in the staining patterns between BNW7p10c5, which showed perinuclear staining, and the other antibodies, which showed cytoplasmic staining, was observed, suggesting that they are staining viral proteins that are localized to different areas of the cell (Figure 1). Two of the immortalized B cell clones, BNW7p5c4 and BNW7p10c5, were further characterized to identify expressed surface markers using flow cytometry and both were observed to express IgG and CD21, suggesting they were indeed memory B cells (Supplementary Figure 2).

Antibody Binding to PRRSV Isolates

Antibody containing supernatants from immortalized B cells were evaluated for their ability to bind a panel of diverse PRRSV strains. A total of 7 PRRSV-2 (ATP, VR2332, MN184, 1-7-4, 1-4-4, 1-3-4, and 1-26-2) and 2 PRRSV-1 (SDEV and Lelystad virus) strains were used for examination of antibody binding (Table 1) and their phylogenetic relationships are shown in the supplementary material (Supplementary Figure 3). Serum from both BNW4 and BNW7 pigs were able to bind all the viruses examined (Table 1). Antibody containing supernatants from immortalized B cell cultures were able to bind all the PRRSV-2 strains examined, but neither of the PRRSV-1 strains examined (Table 1). Positive control antibody SR30-A was able to bind all viruses tested. Negative control serum from a PRRSV naïve pig was unable to bind any of the viruses tested.

Antibody Binding to PRRSV Antigens

Antibodies secreted from immortalized B cells were evaluated for their ability to bind recombinant PRRSV-2 proteins (Table 2). Supernatants from immortalized multi-B cell populations BNW7p1, BNW7p9 and BNW4p14 and immortalized B cell clones BNW7p5c4, and BNW7p10c5 were tested by ELISA for reactivity against 13 recombinant PRRSV-2 proteins. Serum from pig BNW4 and BNW7 were used to evaluate the reactivity of all antibodies present within each animal. Serum from both animals showed strong reactivity to GP3, GP4, GP5, GP5-M complex protein, M 5’ (N-terminal), N, NSP2P, NSP7, and NSP8 and weak reactivity to M 3’ (C-terminal) and NSP4 (Table 2). No binding of BNW7 serum was observed against GP2 or NSP11, while BNW4 serum showed weak reactivity to both (Table 2). BNW7p9, BNW7p1, BNW7p5c4 and BNW4p14 bound to both GP5 and the GP5-M complex protein, suggesting these B cells secreted GP5 specific antibodies (Table 2). BNW7p10c5 did not bind any of the proteins examined, but it showed similar staining to that observed from antibodies specific to equine arteritis virus (EAV) nonstructural proteins, located in the endoplasmic reticulum (ER) of infected cells (46). Arterivirus non-structural proteins have been shown to concentrate in the host ER, where they are involved in control of host protein transcription and viral replication (46–48). This suggests that BNW7p10c5 may bind a viral non-structural protein, that we did not examine in this experiment.

Viral Neutralization Activity of Antibodies Secreted by Immortalized B Cells

Antibodies from B cell clonal populations BNW7p5c4 and BNW7p10c5 were examined for their capacity to neutralize both homologous and heterologous PRRSV-2 strains. Because these pigs were vaccinated using ATP virus, the presence of antibodies against ATP was considered homologous neutralization. Heterologous neutralization was examined by looking at neutralizing activity against PRRSV-2 VR2332 strain, which the animals were not exposed to and which has a 10% difference in nucleotide sequence as compared to the ATP strain (Supplementary Figure 3). Serum antibodies from both pigs were able to neutralize ATP, VR2332, and SDEV viruses with extremely high neutralization titers against the PRRSV-2 strains (Supplementary Figure 1). Antibodies from supernatants were concentrated to ensure that lack of neutralizing activity was not due to low antibody levels and the concentration of IgG was determined in order to equalize antibody concentrations between clones. The highest antibody level tested was 137.5 μg/ml of IgG for BNW7p5c4 and BNW7p10c5. Each concentrated supernatant was examined for its neutralizing ability starting at 137.5 μg/ml and diluted 2-fold down to 2.1 μg/ml. A 50/50 mixture of antibodies from the two clones, BNW7p5c4 and BNW7p10c5, were tested for neutralizing activity to examine a possible polyclonal neutralization response. Concentrated supernatants...
from the GP5-binding BNW7p5c4 clone were observed to have a 50% neutralization titer against ATP virus at a concentration of 34.4 µg/ml IgG (Figure 2A). BNW7p10c5 was unable to neutralize ATP virus. The mixed sample containing both BNW7p5c4 and BNW7p10c5 was neutralizing, similar to what would be expected of a similar concentration of BNW7p5c4 supernatant alone (Figure 2A). This suggests that despite the ability of BNW7p10c5 to bind all PRRSV-2 viruses examined, it was non-neutralizing. Neither B cell supernatant (BNW7p5c4 or BNW7p10c5) was able to neutralize VR2332 or SDEU viruses, even when mixed together (Figures 2B, C), suggesting the neutralizing activity of BNW7p5c4 was specific to the ATP strain even though it was able to bind all PRRSV-2 strains examined, as shown in Table 1.

**DISCUSSION**

The PRRSV envelope glycoprotein GP5 has long been thought to be the major antigen involved in virus neutralization (8, 11, 49, 50). GP5 is encoded by the ORF5 gene, which has been widely used for classification and analysis of PRRSV strains due to its immunological significance and polymorphic nature (51). Sequencing of PRRSV to examine relationships between strains has mainly been performed using ORF5 sequences and RFLP typing (51–53). Numerous neutralization studies have concentrated solely on the PRRSV GP5 protein and early in infection pigs show a strong antibody response to the GP5 protein (49, 50, 54). In this study we showed a similar propensity toward GP5 immunity with 4 out of our 5 PRRSV-
binding immortalized B cell populations secreting GP5-specific antibodies, thus pointing toward GP5 being a dominant antigen in the anti-PRRSV immune response.

This study identified and isolated porcine derived PRRSV neutralizing antibodies and confirmed that GP5 contains a neutralizing epitope. Several studies have claimed that GP5 specific antibodies are non-neutralizing, however the data generated in this study contradicts these findings (19, 20). Porcine GP5-specific mAb BNW7p5c4 was shown to be able to achieve a 50% inhibition of homologous ATP virus at 34.4 µg/ml (Figure 2A). Previous research determined that while GP5 is essential for virus formation and is responsible for adsorption to the host cell, it is not essential for virus entry (22, 55, 56). Li et al. showed that titers of antibody against the ectodomain of GP5 did not correlate with viral neutralizing antibody titers, suggesting that GP5 is not solely responsible for neutralization (20). It has also been demonstrated that pigs lacking sialoadhesin (Sn/Siglec-1/CD169) (the host macrophage protein that GP5 interacts with) are permissive to PRRSV infection, while pigs lacking CD163 (the host protein in which the GP2-GP3-GP4 complex interacts with) are completely resistant to virus infection (57, 58). Based on current knowledge of PRRSV infection and historically ineffective GP5-based vaccine platforms, full sterilizing immunity may not be achievable by induction of GP5 antibody alone (18, 20, 29, 59). More likely, the GP5-specific antibody, BNW7p5c4, inhibits infection but does not permanently prevent it. Our data, along with information from the literature, suggests that the BNW7p5c4 antibody is able to block viral binding to the host cell, thus lowering the ability of the virus to bind and infect the cell. However, since the GP2-GP3-GP4 complex on the virus remains intact and functional, rare viral entry events may still occur allowing for very low levels of infection. This theory on GP5 neutralization would explain some of the confusion and disagreement about the role of GP5 in neutralization. This could also present a reason why the virus persists, as the majority of neutralizing antibodies that we identified are directed toward GP5 and not the proteins responsible for viral entry (GP2, GP3, and GP4).

Homologous neutralization of virus is the most common outcome of exposure to PRRSV, either through vaccination or natural infection. In this study we identified that antibodies secreted from GP5-specific BNW7p5c4 B cells can neutralize homologous virus (ATP), but not heterologous virus (VR2332) (Figure 2). This outcome is not surprising, as antibodies against homologous virus are very common in pigs exposed to PRRSV, however the ability of the antibody to bind the VR2332 strain, but not neutralize it is an interesting observation. It appears the isolated mAb, BNW7p5c4, has different properties depending on which virus it is bound to; becoming a neutralizing antibody against ATP, but a non-neutralizing antibody against VR2332. The cause of this functional discrepancy is not known. It is possible that antibody avidity (total strength of antibody binding against antigen) to the epitope differs between the viruses, with stronger, long lasting binding to homologous virus and a short duration, weak binding to heterologous virus, which contributes to its neutralizing ability. Longer periods of antigen-antibody interactions should, in theory, improve elimination of a pathogen and increase positive feedback signals to B cells. Very few published studies have investigated antibody avidity to PRRSV. Ko et al. observed that vaccinated pigs that produced

![Table 1](https://www.frontiersin.org/articles/10.3389/fimmu.2021.638493/full#tab1)

**Table 1 | Antibody binding to porcine reproductive and respiratory syndrome (PRRSV) strains.**

| Virus sample | PRRSV-2 | PRRSV-1 |
|--------------|---------|---------|
| ATP          | ++      | +       |
| VR2332       | +       | +       |
| MN184        | +       | +       |
| 1-7-4        | +       | +       |
| 1-4-4        | +       | +       |
| 1-3-4        | +       | +       |
| 1-26-2       | +       | +       |
| SDEU         | +       | +       |
| Lelystad     | +       | +       |

*+, antibody containing sample bound to the PRRSV tested; –, no binding detected via IFA. Representative data from three repeat experiments.

![Table 2](https://www.frontiersin.org/articles/10.3389/fimmu.2021.638493/full#tab2)

**Table 2 | Antibody binding to porcine reproductive and respiratory syndrome (PRRSV) proteins.**

| Antibody | Structural proteins | Non-structural proteins |
|----------|---------------------|------------------------|
|          | GP2 | GP3 | GP4 | GP5 | GP5-M | M 3' | M 5' | N  | NSP2P | NSP4 | NSP7 | NSP8 | NSP11 |
| BNW4 Serum | + | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | + | +++ | +++ | + |
| BNW7 Serum | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | + | +++ | +++ | – |
| BNW4 p14 | – | – | ++ | + | + | – | – | – | – | – | – | – | – |
| BNW7 p1 | – | – | ++ | ++ | – | – | – | – | – | – | – | – | – |
| BNW7 p5c4 | – | – | ++ | ++ | – | – | – | – | – | – | – | – | – |
| BNW7 p9 | – | – | – | + | + | – | – | – | – | – | – | – | – |
| BNW7 p10c5 | – | – | – | – | – | – | – | – | – | – | – | – | – |

++, high reactivity (OD value >2); +, moderate reactivity (OD value 1–2); +, low reactivity (OD value <1 and above the cut-off); –, no reactivity (OD value below the cut-off value). Combined representative data from six repeat experiments.
antibodies with high relative avidity indexes (RAI) had decreased and shortened viremia in response to viral challenge (60). Similar results were shown by Islam et al., where longer periods of viremia, as opposed to either quick clearance of virus or rebound infection, were associated with the development of heterologous and broadly neutralizing antibodies (61). It is possible that avidity also plays a role in the development of cross-neutralizing antibodies, with high avidity antibodies being more likely to cross-neutralize diverse viral strains.

The development of broadly neutralizing antibodies against PRRSV is rare and difficult to replicate (32). Based on our findings that all five isolated B cell populations secreted broadly binding antibodies against a diverse group of PRRSV-2 strains, we propose that these antibodies were generated via repeated positive antigen selection of a conserved region of GP5. Many previous studies have shown that multiple varied virus and vaccine exposures lead to improved immunity and most likely broad PRRSV binding, as observed in this study (31, 34, 36, 62).

This study shows the first ever isolation of a porcine PRRSV neutralizing mAb, it confirms that PRRSV GP5 contains a neutralizing epitope, and it suggests that broad binding, non-neutralizing antibodies may precede those that are broadly neutralizing. However, we propose, based on known viral mechanics and our results, that while GP5-specific antibodies aid in virus neutralization, they are most likely not the only PRRSV epitope-specific antibodies involved. In this study, we showed that pigs exposed to an array of genetically distant PRRSV strains over time, developed antibodies that were broadly reactive to diverse PRRSV. Future vaccines against PRRSV may be more effective at inducing protection against a broad range of PRRSV if they contain multiple isolates or genetically distinct epitopes that are present in the field. The addition of a multi-strain vaccine booster may also increase vaccine efficacy against a broad range of PRRSV strains. While these results shed new light on PRRSV neutralization, much is still unknown. The isolation of additional porcine-derived antibodies using the techniques used in this study should uncover further information about PRRSV neutralization. In particular, isolation of GP2, GP3, and GP4 specific antibodies will likely uncover additional neutralizing or potentially broadly neutralizing antibodies and combining monoclonal antibodies with binding specificities to different viral proteins may elucidate methods leading toward broadly neutralizing antibody activity.

**DATA AVAILABILITY STATEMENT**

The data sets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/genbank/, EF532801.1, MT269876, MT269877, MN175677, MT269878, MT269879, KF724400, MN175678, M96262.2.

**AUTHOR CONTRIBUTIONS**

JY, CD, SG, and MM conceived the study and participated in its design and coordination. JY performed experiments and interpreted results. JY wrote the first draft of the manuscript. JY, CD, and SG contributed to manuscript revision and read and approved the final manuscript. All authors contributed to the article and approved the submitted version.
FUNDING

Funding for this project was provided by USDA NIFA grant 2016-67015-24928 and JY was partially funded through the Sam Maheswaran Graduate Fellowship. SG is supported by a UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme Grant to the Pirbright Institute (BBS/E/1/00007031).

ACKNOWLEDGMENTS

The authors are grateful for the assistance of David Goldeck and Jack Hayes of The Pirbright Institute for teaching JY techniques related to B cell immortalization and to AIMM Therapeutics for providing the immortalization protocols, vector, and supplies.

REFERENCES

1. Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J. Diseases of Swine. 11th Edition. Hoboken, NJ: Wiley-Blackwell (2019).
2. Horter DC, Pogranichniy RM, Chang CC, Evans RB, Yoon KJ, Zimmerman JJ. Characterization of the carrier state in porcine reproductive and respiratory syndrome virus infection. Vet Microbiol (2002) 86:213–28. doi: 10.1016/S0378-1135(02)00013-5
3. Allende R, Laegreid WW, Kutish GF, Galeota JA, Wills RW, Osorio FA. Porcine reproductive and respiratory syndrome virus: description of persistence in individual pigs upon experimental infection. J Virol (2000) 74:10834–7. doi: 10.1128/JVI.74.22.10834-10837.2000
4. Holtkamp D, Kleibenstein J, Neumann E. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod (2013) 21:72–84. doi: 10.31274/ans_air-140814-28
5. Nathues H, Alarcón P, Rushton J, Jolli R, Fiebig K, Jimenez M, et al. Cost of porcine reproductive and respiratory syndrome virus at individual farm level - An economic disease model. Prev Vet Med (2017) 142:16–29. doi: 10.1016/j.prevetmed.2017.04.006
6. Lovig CI, Osorio FA, Murtaugh MP, Zuckermann FA. Innate and adaptive immunity against Porcine Reproductive and Respiratory Syndrome Virus. Vet Immunol Immunopathol (2015) 167:3–14. doi: 10.1016/j.vetimm.2015.07.003
7. Rahe MC, Murtaugh MP. Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Viruses. Viruses (2017) 9:148. doi: 10.3390/v9040148
8. Popescu LN, Tribble BR, Chen N, Rowland RRR. GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) as a target for homologous and broadly neutralizing antibodies. Vet Microbiol (2017) 209:90–6. doi: 10.1016/j.vetmic.2017.04.016
9. Pirzadeh B, Dea S. Monoclonal antibodies to the ORF5 product of porcine reproductive and respiratory syndrome virus define linear neutralizing determinants. J Gen Virol (1997) 78 (Pt 8):1867–73. doi: 10.1099/0022-1317-78-8-1867
10. Yang L, Frey ML, Yoon KJ, Zimmerman JJ, Platt KB. Categorization of North American porcine reproductive and respiratory syndrome viruses: epitopic profiles of the N, M, GP5 and GP3 proteins, and susceptibility to neutralization. Arch Virol (2000) 145:1599–619. doi: 10.1007/s007050070079
11. Ostrowski M, Galeota JA, Jar AM, Platt KB, Osorio FA, Lopez OJ. Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. J Virol (2002) 76:4241–50. doi: 10.1128/JVI.76.9.4241-4250.2002
12. Plagemann PG, Rowland RR, Faaberg KS. The primary neutralization epitope of porcine reproductive and respiratory syndrome virus strain VR-2332 is located in the middle of the GP5 ectodomain. Arch Virol (2002) 147:2327–47. doi: 10.1007/s0070502-0887-2
13. Wisink EH, Kroese MV, Maneschijn-Bonsing JG, Meulenberg JJ, van Rijn PA, Rijswijck FA, et al. Significance of the oligosaccharides of the porcine reproductive and respiratory syndrome virus glycoproteins GP2a and GP5 for infectious virus production. J Gen Virol (2004) 85:3715–23. doi: 10.1099/vir.0.80402-0
14. Jiang W, Jiang P, Wang X, Li Y, Du Y. Influence of porcine reproductive and respiratory syndrome virus GP5 glycoprotein N-linked glycans on immune responses in mice. Virus Genes (2007) 35:663–71. doi: 10.1007/s11262-007-0131-y
15. Kim WI, Kim JJ, Cha SH, Wu WH, Cooper V, Evans R, et al. Significance of genetic variation of PRRSV ORFs in virus neutralization and molecular determinants corresponding to cross neutralization among PRRS viruses. Vet Microbiol (2013) 162:10–22. doi: 10.1016/j.vetmic.2012.08.005
16. Vanhee M, Van Breumad W, Costers S, Geldhof M, Noppe Y, Nauwynck H. Characterization of antigenic regions in the porcine reproductive and respiratory syndrome virus by the use of peptide-specific antibodies. Vaccine (2011) 29:4794–804. doi: 10.1016/j.vaccine.2011.04.071
17. Xu XF, Wang ZS, Zhang Q, Li ZC, Ding L, Li W, et al. Baculovirus as a PRRSV and PCV2 bivalent vaccine vector: baculovirus virions displaying simultaneously GP5 glycoprotein of PRRSV and capsid protein of PCV2. J Virol Methods (2012) 179:359–66. doi: 10.1016/j.jviromet.2011.11.023
18. Zhou JX, Xue JD, Yu T, Zhang JB, Liu Y, Jiang N, et al. Immune responses in pigs induced by recombinant canine adenovirus 2 expressing the glycoprotein 5 of porcine reproductive and respiratory syndrome virus. Vet Res Commun (2010) 34:371–80. doi: 10.1007/s11259-010-9364-7
19. Leng CL, An TQ, Chen JZ, Gong DQ, Peng JM, Yang YQ, et al. Highly pathogenic porcine reproductive and respiratory syndrome virus GP5 B antigenic region is not a neutralizing antigenic region. Vet Microbiol (2012) 159:273–81. doi: 10.1016/j.vetmic.2012.06.018
20. Li J, Murtaugh MP. Dissociation of porcine reproductive and respiratory syndrome virus neutralization from antibodies specific to major envelope protein surface epitopes. Virology (2012) 433:367–76. doi: 10.1016/j.virol.2012.08.026
21. Das PB, Dinh PX, Ansari IH, de Lima M, Osorio FA, Pattanaik AK. The minor envelope glycoproteins GP2a and GP4 of porcine reproductive and respiratory syndrome virus interact with the receptor CD163. J Virol (2010) 84:3731–40. doi: 10.1128/JVI.01774-09
22. Calvert JG, Slade DE, Shields SL, Jolli R, Mannan RM, Ankenbauer RG, et al. CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses. J Virol (2007) 81:7371–9. doi: 10.1128/JVI.00513-07
23. Tian D, Wei Z, Zevenhoven-Dobbe JC, Liu R, Tong G, Snijder EJ, et al. Arterivirus minor envelope proteins are a major determinant of viral tropism in cell culture. J Virol (2012) 86:3701–12. doi: 10.1128/JVI.00836-11
24. Costers S, Lefebvre DJ, Van Doorselaere J, Vanhee M, Delputte PL, Nauwynck HJ. GP4 of porcine reproductive and respiratory syndrome virus

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.638493/full#supplementary-material

Ying Fang (University of Illinois, Champaign, IL) graciously provided the recombinant PRRSV-2 GP2, GP3 and GP4 proteins used to identify PRRSV-specific antibodies. The authors would like to thank the University of Minnesota Flow Cytometry Resource for aid in designing and implementing cell sorting experiments. The authors acknowledge the University of Minnesota University Imaging Centers for providing resources that contributed to the research results reported within this manuscript.
contains a neutralizing epitope that is susceptible to immunosseletion in vitro. 

Arch Virol (2010) 155:371–8. doi: 10.1007/s00705-009-0582-7

25. Costers S, Vanhee M, Van Breedam W, Van Doorselaere J, Geldhof M, Nauwynck HJ. GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution. 

Virus Res (2010) 154:104–13. doi: 10.1016/j.virusres. 2010.08.026

26. Vanhee M, Costers S, Van Breedam W, Geldhof MF, Van Doorselaere J, Nauwynck HJ. A variable region in GP4 of European-type porcine reproductive and respiratory syndrome virus induces neutralizing antibodies against homologous but not heterologous virus strains. 

Viral Immunol (2010) 23:403–13. doi: 10.1089/vim.2010.0025

27. Zhou L, Ni YY, Piñeyro P, Sanford BJ, Cossaboom CM, Dryman BA, et al. DNA shuffling of the GP3 genes of porcine reproductive and respiratory syndrome virus (PRRSV) produces a chimeric virus with an improved cross-neutralizing ability against a heterologous PRRSV strain. 

Virology (2012) 434:96–109. doi: 10.1016/j.viro.2012.09.005

28. Jiang W, Jiang P, Li Y, Wang X, Du Y. Analysis of immunogenicity of minor envelope protein GP3 of porcine reproductive and respiratory syndrome virus in mice. 

Virus Genes (2007) 35:695–704. doi: 10.1007/s11262-007-0143-7

29. Plagemann PG. Neutralizing antibody formation in swine infected with seven strains of porcine reproductive and respiratory syndrome virus as measured by indirect ELISA with peptides containing the GP5 neutralization epitope. 

Viral Immunol (2006) 19:285–93. doi: 10.1089/vim.2006.19.285

30. Osorio FA, Galeota JA, Nelson E, Brodersen B, Doster A, Wills R, et al. Passive antibody responses to homologous and heterologous type I PRRSV vaccine strains of porcine reproductive and respiratory syndrome virus. 

J Vet Med Sci (2009) 71:1249–56. doi: 10.1292/jvms.2009.1249

31. Martinez-Lobo FJ, Díez-Fuentes F, Simarro I, Castro JM, Prieto C. Porcine Reproductive and Respiratory Syndrome Virus isolates differ in their susceptibility to neutralization. 

Vaccine (2011) 29:6928–40. doi: 10.1016/j.vaccine.2011.07.076

32. Trible BR, Popescu LN, Monday N, Calvert JG, Rowland RR. A single amino acid deletion in the matrix protein of porcine reproductive and respiratory syndrome virus confers resistance to a polyclonal Swine antibody with broadly neutralizing activity. 

J Virol (2015) 89:6515–20. doi: 10.1128/JVI.01328-14

33. Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccine. 

Vaccine (2002) 20:329–30. doi: 10.1016/S0264-410X(02)00344-7

34. Robinson SR, Li J, Nelson EA, Murtaugh MP. Broadly neutralizing antibodies to the envelope protein GP3 of porcine reproductive and respiratory syndrome virus (PRRSV) nonstructural proteins and implications for diagnostic detection and differentiation of PRRSV types I and II. 

Clin Vaccine Immunol (2009) 16:628–35. doi: 10.1128/CVI.00483-08

35. Molupuri P, Zimmerman JJ, Hermann J, Johnson CR, Cano JP, Yu W, et al. Antigen-specific B-cell responses to porcine reproductive and respiratory syndrome virus infection. 

J Virol (2008) 82:358–70. doi: 10.1128/JVI.01023-07

36. Rahe MC, Murtaugh MP. Interleukin-21 Drives Proliferation and Differentiation of PRRSV GP5 Porcine Monoclonal Antibody

Young et al. PRRSV GP5 Porcine Monoclonal Antibody receptor-positive human memory B cells by genetic programming. 

Nat Med (2010) 16:123–8. doi: 10.1038/nm.2071

Brown E, Lawson S, Welshb Ch, Chandrakarajah J, Li J, Murtaugh MP, et al. Antibody response to porcine reproductive and respiratory syndrome virus (PRRSV) nonstructural proteins and implications for diagnostic detection and differentiation of PRRSV types I and II. 

Clin Vaccine Immunol (2009) 16:628–35. doi: 10.1128/CVI.00483-08

38. Zhang SL, Tan HC, Hanson BJ, Ooi EE. A simple method for Alexa Fluor dye labelling of dengue virus. 

J Virol Methods (2010) 167:172–7. doi: 10.1016/j.jviromet.2010.04.001

39. Kumar S, Stecher G, Li M, Knyz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. 

Mol Biol Evol (2018) 35:1547–9. doi: 10.1093/molbev/msy096

40. Rahe MC, Murtaugh MP. Interleukin-21 Drives Proliferation and Differentiation of Porcine Memory B Cells into Antibody Secreting Cells. 

PLoS One (2017) 12:e0171171. doi: 10.1371/journal.pone.0171171

41. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of stable monoclonal antibody-producing B cell

Frontiers in Immunology | www.frontiersin.org 9 February 2021 Volume 12 Article 638493
59. Kim WI, Yoon KJ. Molecular assessment of the role of envelope-associated structural proteins in cross neutralization among different PRRS viruses. *Virus Genes* (2008) 37:380–91. doi: 10.1007/s11262-008-0278-1

60. Ko SS, Seo SW, Sunwoo SY, Yoo SJ, Kim MH, Lyoo YS. Efficacy of commercial genotype 1 porcine reproductive and respiratory syndrome virus (PRRSV) vaccine against field isolate of genotype 2 PRRSV. *Vet Immunol Immunopathol* (2016) 172:43–9. doi: 10.1016/j.vetimm.2016.02.016

61. Islam ZU, Bishop SC, Savill NJ, Rowland RR, Lunney JK, Trible B, et al. Quantitative analysis of porcine reproductive and respiratory syndrome (PRRS) viremia profiles from experimental infection: a statistical modelling approach. *PloS One* (2013) 8:e83567. doi: 10.1371/journal.pone.0083567

62. Robinson SR, Rahe MC, Gray DK, Martins KV, Murtaugh MP. Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge. *Virus Res* (2018) 248:13–23. doi: 10.1016/j.virusres.2018.01.015

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Young, Dvorak, Graham and Murtaugh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.